One of the adjuncts in the treatment and prognostication of breast cancer patients is the determination of hormone status, such as estrogen (ER) and progesterone receptors (PR), and human epidermal receptor 2 (HER2) receptors. This evidence concerns the gene ERBB2 and breast carcinoma.